ECGI Holdings (OTC:ECGI) Stock, Quote.Headers.trade-ideas

ECGI Holdings Inc is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The Company owns and manages a five-acre vineyard in Lake County, California, involved in cultivating Petite Sirah, known for its bold and rich character, aligns with the growing demand for high-quality wine experiences.

Cannabis

News

Markets

ECGI

ECGI HOLDINGS INC. (OTCPK:ECGI), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, provided an update on the continued expansion of its soon-to-be-acquired cannabis brand, 8-Bit Buds.

ECGI&#39;s 8-Bit Cannabis Expands Distribution To 65 Stores

ECGI HOLDINGS INC. (OTCPK:ECGI), D/B/A Elite Cannabis Group Incorporated, announced the signing of a binding letter of intent toward the acquisition of the key personnel, intellectual property, business operations, and future b

ECGI To Acquire 8bit Cannabis Brand As Target Distribution Widens To 20 Dispensaries

ECGI Holdings Inc. (OTCPK:ECGI), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, signed a letter of intent with East West Pharma Group, Inc., a Wyoming corp

ECGI To Acquire East West Pharma Group

ECGI Holdings Inc

Loop Capital analyst Alton Stump maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Hold and lowers the price target from $50 to $45.

Price Target

Analyst Ratings

CBRL

Loop Capital Maintains Hold on Cracker Barrel Old, Lowers Price Target to $45

WIIM

CHWY

Chewy shares are trading lower after the company announced the public offering of shares by a selling stockholder and a concurrent share repurchase.

Biotech

General

BNTX

Pfizer And BioNTech Receive Positive CHMP Opinion For Omicron KP.2-Adapted COVID-19 Vaccine In EU, Awaiting European Commission Authorization To Ship

Morgan Stanley analyst Ravi Shanker downgrades FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Equal-Weight to Underweight and lowers the price target from $215 to $200.

Downgrades

Morgan Stanley Downgrades FedEx to Underweight, Lowers Price Target to $200

Ahead of the 2024 presidential election, the front yard of Warren Buffett in Omaha, Nebraska, could play a pivotal role in shaping the outcome.
What Happened: In Nebraska's 2nd Congressional District, a single electoral vote could be crucial. Neighbors are closely watching to see if a blue-dot sign appears outside Buffett's home. These signs, part of a grassroots effort, symbolize Democratic solidarity in a predominantly Republican area, The Wall Street Journal <a href="https://www.wsj.com/us-news/blue-dot-signs-warren-buffett-presidential-race-a9a26579">report</a> on Friday.
Buffett's history of supporting Barack Obama and Hillary Clinton has raised hopes among Democrats. One neighbor even sent Buffett a handwritten letter urging him to display a blue-dot sign. His daughter, Susan Buffett, already has two signs in her yard.
The blue-dot campaign was initiated by Jason Brown, who lives near Buffett. Inspired by the Democratic National Convention, Brown's idea has led to thousands of signs being distributed across Omaha. The signs are especially concentrated in Buffett's upscale neighborhood.
See Also: <a href="https://www.benzinga.com/news/24/09/40950674/data-scientist-who-called-2020-election-correctly-says-its-gone-from-drastic-landslide-in-trumps-dir?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist Who Called 2020 Election Correctly Says Its Gone From &#8216;Drastic Landslide In Trump&#8217;s Direction To A drastic landslide For Harris&#8217;</a>
Brown and his wife, Ruth Huebner-Brown, have distributed over 5,000 signs and plan to produce more. They request a $10 contribution to cover costs and pledge to donate any profits. Despite the grassroots effort, Buffett has not commented on whether he will display a sign.
Why It Matters: The influence of Warren Buffett in political circles has been significant over the years. In 2017, Buffett surprisingly <a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr">expressed support for Donald Trump'</a>s cabinet choices, indicating his pragmatic approach to politics. This bipartisan stance adds weight to his potential endorsement in the current election.
Recently, Elon Musk speculated that this time, Buffett might be <a href="https://www.benzinga.com/general/politics/17/01/8927406/trumps-newest-unlikely-ally-warren-buffett">positioning for a Kamala Harris win</a>, given his $277 billion cash reserve. This speculation comes amid a divided business community, with hedge fund manager John Paulson warning of a market exit if Harris wins. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump In Trouble: Vice President Harris Has Record 6-Point Lead In 2024 Election Poll After Debate, Posts Highest Rankings In Key Demographics</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Trump Vs. Harris: Will Warren Buffett Display A Blue Or Red Dot In His Front Yard? Neighbors Wait To See Who The Oracle Of Omaha Is Supporting

The European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy&nbsp;(semaglutide 2.4 mg) label.
The label <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=170500" rel="noreferrer noopener">update</a> incorporates data showing that Wegovy, when added to the standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40813963/ozempic-maker-novo-nordisk-touts-encouraging-data-from-new-obesity-pill-showing-double-weight-los" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy</a>
Heart failure affects at least 64 million people worldwide and is especially prevalent in obese and/or type 2 diabetes patients.
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure, comprising approximately 50% of all heart failure cases.
The positive opinion is based on the results from the STEP HFpEF and STEP HFpEF-DM trials.
In both trials, Wegovy&nbsp;demonstrated greater reductions in heart failure-related symptoms, improvements in physical limitations, and weight loss compared to placebo.
The label update also incorporates data that showed that participants receiving Wegovy&nbsp;achieved a greater increase in exercise function, as measured by the difference in 6-minute walking distance (6MWD) from baseline to week 52, compared to those receiving placebo.
The recommendation to incorporate the data from the STEP HFpEF trials adds to the recent Wegovy&nbsp;EMA label update, which included data from the SELECT landmark trial to reflect the risk reduction of heart attack, stroke, and cardiovascular death.
With the positive opinion from the CHMP, Novo Nordisk expects implementation of the EU label update shortly, following a linguistic review process by the EMA.
As communicated earlier this year, Novo Nordisk will resubmit to the FDA in 2025 to include data from the STEP HFpEF trials in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40229407/novo-nordisk-withdraws-wegovy-fda-heart-failure-submission-terminates-development-of-two-early-st" rel="noreferrer noopener">Wegovy&nbsp;label in the U.S</a>.
In its quarterly earnings report, Novo Nordisk announced that it had submitted the Wegovy STEP HFpEF trials data for regulatory review in the U.S. and EU in January 2024. However, following discussions with the FDA, the company withdrew the submission.
Novo Nordisk said it plans to resubmit the file in early 2025, incorporating additional data, including findings from the kidney outcomes trial for its once-weekly injectable semaglutide 1.0 mg.
Price Action: NVO stock is down 0.42% at $134.32 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa" target="_blank" rel="noreferrer noopener">Abbott Laboratories&#8217; Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst</a>.</li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

Health Care

European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure

Morgan Stanley analyst Dara Mohsenian downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and maintains the price target from $185 to $185.

Morgan Stanley Downgrades PepsiCo to Equal-Weight, Maintains Price Target to $185

ATNM

Actinium Pharmaceuticals Publishes Phase 3 SIERRA Trial Results Of Iomab-B In Journal Of Clinical Oncology, Highlights Success In Achieving Complete Remission And Event-Free Survival

Morgan Stanley analyst Rashad Kawan maintains Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) with a Overweight and raises the price target from $9.9 to $10.95.

Morgan Stanley Maintains Overweight on Haleon, Raises Price Target to $10.95

Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) has been outperforming its dog-themed meme coin rivals, prompting calls for a surge to $10 billion and beyond.
What Happened: Pseudonymous crypto trader SomSpencer declared the arrival of the "meme season" in the crypto market, emphasizing the importance of PEPE as a key indicator. 
He stated that the meme coin has broken out and described Pepe as "the &#8220;meme index" for this crypto cycle, suggesting that its performance is a reliable indicator of the market&#8217;s risk appetite.
The trader <a href="https://x.com/SomSpencer1771/status/1836790093975031916">anticipates</a> PEPE to set new all-time highs in the current quarter, possibly before the election. He also predicts a significant liquidity shift from PEPE as it approaches a $10B billion market cap, with liquidity likely to rotate into midcaps and microcaps.
He concluded by stating, "No one is bullish enough. It&#8217;s time for an up-only market."
Another trader <a href="https://x.com/cryptojourneyrs/status/1836868278943371341">predicts</a> Pepe to overtake Shiba Inu based on Pepe&#8217;s market cap:trading volume ratio.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40876130/dogecoin-millionaire-highlights-pepe-and-dogecoin-as-two-biggest-meme-narratives-for-2025-">&#8216;Dogecoin Millionaire&#8217; Highlights Pepe and Dogecoin As &#8216;Two Biggest Meme Narratives For 2025,&#8217; Shiba Inu, Floki To Follow</a>
Why It Matters: IntoTheBlock data shows a 231.4% increase in large transaction volume and a 33.5% rise in daily active addresses. Transactions greater than $100,000 increased from 80 to 255 in the past two days.
Pepe's seven-day and 30-day gains stand at 13% and 8%, respectively. It has outperformed its rivals Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), up 3% and 6% over the past 30 days. In the past seven days, DOGE and SHIB are up 1% and 6%.
Pepe&#8217;s 24-hour trading volume at $1.7 billion exceeds that of both Dogecoin ($741.5 million) and Shiba Inu ($405 million) combined.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40881260/trader-shares-3-contrarian-takes-trump-meme-coin-an-obvious-buy-and-these-2-cryptos-are-de">Trader Shares &#8216;3 Contrarian Takes:&#8217; TRUMP Meme Coin &#8216;An Obvious Buy&#8217; And These 2 Cryptos Are &#8216;Deep Value&#8217; And Will Be &#8216;Outperforming Soon&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Pepe Leapfrogs Dogecoin, Shiba Inu In 30-Day Gains, Trading Volume: 'No One Is Bullish Enough,' Says Trader

CHPT

ChargePoint Says It Has Secured NEVI Award Funding To Proliferate EV Charging On California Highways

Asset Sales

NovaBay Pharmaceuticals Reaches Definitive Deal To Sell Avenova Assets For $9.5M, Expected To Close Q4 2024

KOPN

Kopin Corporation Announces Pricing Of $27M Public Offering Of Common Stock And Pre-funded Warrants; Closing Of The Offering Is Expected To Occur On Or About September 23

Global Engine Group Announces Pricing Of $8M Initial Public Offering At Public Offering Price Of $4.00 Per Share

Across the recent three months, 4 analysts have shared their insights on Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.0, a high estimate of $45.00, and a low estimate of $45.00. Marking an increase of 6.31%, the current average surpasses the previous average price target of $42.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833694_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Essential Utilities's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Fowler</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jonathan Reeder</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Essential Utilities. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Utilities compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Essential Utilities's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Essential Utilities's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WTRG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Utilities analyst ratings.</a>
<h2>Unveiling the Story Behind Essential Utilities</h2>
Essential Utilities is a Pennsylvania-based holding company for us water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. Essential exited its noncore competitive water and energy services businesses.
<h3>Essential Utilities: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Essential Utilities's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.53%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: Essential Utilities's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Essential Utilities's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Essential Utilities's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.44%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Essential Utilities's debt-to-equity ratio is below the industry average at 1.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WTRG

4 Analysts Have This To Say About Essential Utilities

Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $257.67, with a high estimate of $282.00 and a low estimate of $215.00. Marking an increase of 5.65%, the current average surpasses the previous average price target of $243.89. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833681_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA excels beyond industry benchmarks, reaching 1.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Analyst Ratings For Labcorp Holdings

Analysts' ratings for Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $117.0, a high estimate of $135.00, and a low estimate of $103.00. This upward trend is apparent, with the current average reflecting a 13.15% increase from the previous average price target of $103.40.
<img src="https://www.benzinga.com/files/images/story/2024/1726833658_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Advanced Energy Indus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$128.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Advanced Energy Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Advanced Energy Indus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Advanced Energy Indus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Advanced Energy Indus analyst ratings.</a>
<h2>Get to Know Advanced Energy Indus Better</h2>
Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in the United States, with the rest primarily from Asia and Europe.
<h3>Advanced Energy Indus: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Advanced Energy Indus's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -12.17%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Advanced Energy Indus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Advanced Energy Indus's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Advanced Energy Indus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.88, Advanced Energy Indus faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Analyst Expectations For Advanced Energy Indus's Future

In the last three months, 4 analysts have published ratings on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.25, a high estimate of $48.00, and a low estimate of $38.00. Surpassing the previous average price target of $37.00, the current average has increased by 14.19%.
<img src="https://www.benzinga.com/files/images/story/2024/1726833647_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amkor Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Peter Peng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$48.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amkor Tech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amkor Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amkor Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amkor Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amkor Tech analyst ratings.</a>
<h2>Discovering Amkor Tech: A Closer Look</h2>
Amkor Technology Inc is a provider of outsourced semiconductor packaging and test services to integrated device manufacturers, fabless semiconductor companies, and contract foundries. The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
<h3>Financial Milestones: Amkor Tech's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Amkor Tech showcased positive performance, achieving a revenue growth rate of 0.24% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Amkor Tech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 4.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Amkor Tech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.66%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Amkor Tech's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amkor Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

4 Analysts Assess Amkor Tech: What You Need To Know

During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $265.92, a high estimate of $300.00, and a low estimate of $230.00. Marking an increase of 2.28%, the current average surpasses the previous average price target of $260.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833637_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of IQVIA Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$256.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$288.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$242.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$251.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for IQVIA Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into IQVIA Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>Discovering IQVIA Hldgs: A Closer Look</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>Financial Insights: IQVIA Hldgs</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, IQVIA Hldgs showcased positive performance, achieving a revenue growth rate of 2.31% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): IQVIA Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 5.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IQVIA Hldgs's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 13 Analyst Recommendations For IQVIA Hldgs

Goldman Sachs analyst Jerry Revich maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Neutral and lowers the price target from $72 to $62.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

ECGI Holdings

ECGI Holdings (ECGI) Forecast

ECGI Holdings (OTC:ECGI) Stock, Quote.Headers.trade-ideas